# A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

> **NCT02951182** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 74 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** TEZ
- **DRUG:** IVA
- **DRUG:** VX-440
- **DRUG:** Matched Placebo

## Key facts

- **NCT ID:** NCT02951182
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951182, "A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02951182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*